Allarity expands lab capabilities for stenoparib research and external services
AI Summary- Allarity expanded its laboratory to add proteomics and cell-line research capabilities.
- Approximately 300 protein targets can be measured with the new nCounter panel.
- Stenoparib trials are enrolling patients with ovarian and small cell lung cancers.